178 related articles for article (PubMed ID: 37732946)
1. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
Lee BP; Dodge JL; Terrault NA
Hepatology; 2024 Mar; 79(3):666-673. PubMed ID: 37732946
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
[TBL] [Abstract][Full Text] [Related]
3. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
[TBL] [Abstract][Full Text] [Related]
4. Exploring the landscape of steatotic liver disease in the general US population.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
[TBL] [Abstract][Full Text] [Related]
5. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.
Ochoa-Allemant P; Marrero JA; Serper M
Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38051551
[TBL] [Abstract][Full Text] [Related]
6. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
Lee CM; Yoon EL; Kim M; Kang BK; Cho S; Nah EH; Jun DW
Hepatology; 2024 Jun; 79(6):1393-1400. PubMed ID: 38100294
[TBL] [Abstract][Full Text] [Related]
7. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
[TBL] [Abstract][Full Text] [Related]
8. Poor accuracy and sustainability of the first-step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population.
De Vincentis A; Tavaglione F; Namba S; Kanai M; Okada Y; Kamatani Y; Maurotti S; Pedone C; Antonelli Incalzi R; Valenti L; Romeo S; Vespasiani-Gentilucci U
Aliment Pharmacol Ther; 2024 Jun; 59(11):1402-1412. PubMed ID: 38497224
[TBL] [Abstract][Full Text] [Related]
9. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
[TBL] [Abstract][Full Text] [Related]
10. Differences in the prevalence of NAFLD, MAFLD, and MASLD according to changes in the nomenclature in a health check-up using MRI-derived proton density fat fraction.
Park HJ; Lee S; Lee JS
Abdom Radiol (NY); 2024 Apr; ():. PubMed ID: 38587630
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of Steatotic Liver Disease Among US Adults with Rheumatoid Arthritis.
Vassilopoulos A; Kalligeros M; Vassilopoulos S; Shehadeh F; Benitez G; Kaczynski M; Lazaridou I; Promrat K; Wands JR; Mylonakis E
Dig Dis Sci; 2024 Mar; 69(3):989-1003. PubMed ID: 38183561
[TBL] [Abstract][Full Text] [Related]
12. Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study.
Han E; Lee BW; Kang ES; Cha BS; Ahn SH; Lee YH; Kim SU
Metabolism; 2024 Mar; 152():155789. PubMed ID: 38224909
[TBL] [Abstract][Full Text] [Related]
13. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study.
Moon JH; Jeong S; Jang H; Koo BK; Kim W
EClinicalMedicine; 2023 Nov; 65():102292. PubMed ID: 37954905
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Steatotic Liver Disease Based on a New Nomenclature in the Japanese Population: A Health Checkup-Based Cross-Sectional Study.
Miwa T; Tajirika S; Imamura N; Adachi M; Horita R; Hanai T; Fukao T; Shimizu M; Yamamoto M
J Clin Med; 2024 Feb; 13(4):. PubMed ID: 38398471
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020.
Kalligeros M; Vassilopoulos A; Vassilopoulos S; Victor DW; Mylonakis E; Noureddin M
Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1330-1332.e4. PubMed ID: 37949334
[TBL] [Abstract][Full Text] [Related]
16. Steatotic liver disease-associated all-cause/cause-specific mortality in the United States.
Kim D; Wijarnpreecha K; Cholankeril G; Ahmed A
Aliment Pharmacol Ther; 2024 Jul; 60(1):33-42. PubMed ID: 38649335
[TBL] [Abstract][Full Text] [Related]
17. Fibrosis and steatotic liver disease in US adolescents according to the new nomenclature.
Ma N; Bansal M; Chu J; Branch AD
J Pediatr Gastroenterol Nutr; 2024 May; ():. PubMed ID: 38693784
[TBL] [Abstract][Full Text] [Related]
18. From NAFLD to MASLD: When metabolic comorbidity matters.
Hong S; Sun L; Hao Y; Li P; Zhou Y; Liang X; Hu J; Wei H
Ann Hepatol; 2024; 29(2):101281. PubMed ID: 38135250
[TBL] [Abstract][Full Text] [Related]
19. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.
Loomba R; Wong VW
Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279
[TBL] [Abstract][Full Text] [Related]
20. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU
Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
